Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Sep 2;14:5332. doi: 10.1038/s41467-023-40813-w

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — A Changes in the frequency of PDL1 positive monocytes at baseline and after each of the first 3 cycles of atezolizumab (n = 19, 19, 17, 16 patients at baseline, C1–C3). The left panel is a box and whisker plot where each dot represents the value for an individual patient, the line represents the median, the box represents the interquartile range, and the whiskers represent the spread of the data. The overlayed line graph demonstrates the trend for the individual patients across cycles. The right panel is representative flow cytometry staining for an individual patient at baseline and after cycle 3, as well as the fluorescence minus one (FMO) negative gating control. B Changes in the frequency of PDL1 positive myeloid-derived suppressor cells (MDSC) at baseline and after each of the first 3 cycles of atezolizumab atezolizumab (n = 19, 19, 17, 16 patients at baseline, C1–C3). The left panel is a box and whisker plot representing the median, interquartile range, and data spread with an overlayed line graph demonstrating the trend for the individual patients across cycles. C Changes in the mean fluorescence intensity (MFI) of ICOS on PD1/Ki67 double positive memory CD8 T cells at baseline and after each of the first 3 cycles of atezolizumab atezolizumab (n = 14, 17, 13, 11 patients at baseline, C1–C3). The left panel is a box and whisker plot representing the median, interquartile range, and data spread with an overlayed line graph demonstrating the trend for the individual patients across cycles. Error bars represent the spread of the data. The right panel is a representative flow cytometry histogram for an individual patient at baseline and after cycle 3, as well as the corresponding FMO negative gating control. D Changes in the MFI of ICOS on PD1/Ki67 double positive CD4 T cells at baseline and after each of the first 3 cycles of atezolizumab (n = 18, 18, 16, 14 patients at baseline, C1–C3). The left panel is a box and whisker plot representing the median, interquartile range, and data spread with an overlayed line graph demonstrating the trend for the individual patients across cycles. Statistical comparisons across the course of therapy were performed by ANOVA. Source data are provided as a Source Data file.